These epitopes can be recognized by tumor-infiltrating T cells, but antibodies that block the checkpoint lead to tumor-infiltrating T cell activation and cause tumors to regress, so highly mutated tumors such as melanoma and lung cancer are more sensitive to anti-PD-1/PD-L1 antibody therapy (81, 82). This evidence concerns the gene RPL17 and neoplasm.